Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Operations (Unaudited)

v3.20.2
Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Income Statement [Abstract]    
Revenue
Operating expenses:    
Research and development, net of reimbursements 4,151 4,336
General and administrative 1,532 1,363
Total operating expenses 5,683 5,699
Loss from operations (5,683) (5,699)
Other income:    
Interest income - net 13 29
Total other income 13 29
Net loss $ (5,670) $ (5,670)
Net loss per share of common stock - basic and diluted $ (0.03) $ (0.05)
Weighted average shares of common stock outstanding - basic and diluted 173,001,307 117,197,086